CN104902888A - 施用包含二十二碳五烯酸的组合物的方法 - Google Patents

施用包含二十二碳五烯酸的组合物的方法 Download PDF

Info

Publication number
CN104902888A
CN104902888A CN201380064003.5A CN201380064003A CN104902888A CN 104902888 A CN104902888 A CN 104902888A CN 201380064003 A CN201380064003 A CN 201380064003A CN 104902888 A CN104902888 A CN 104902888A
Authority
CN
China
Prior art keywords
dpa
dha
composition
acid
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380064003.5A
Other languages
English (en)
Chinese (zh)
Inventor
乔治·博博泰斯
阿卜杜勒·阿齐兹·法齐
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Matinas Biopharma Inc
Original Assignee
Matinas Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Matinas Biopharma Inc filed Critical Matinas Biopharma Inc
Priority to CN202010984870.2A priority Critical patent/CN112107570A/zh
Publication of CN104902888A publication Critical patent/CN104902888A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23B—PRESERVATION OF FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES; CHEMICAL RIPENING OF FRUIT OR VEGETABLES
    • A23B20/00—Preservation of edible oils or fats
    • A23B20/30—Preservation of other edible oils or fats, e.g. shortenings or cooking oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
    • A23D9/00—Other edible oils or fats, e.g. shortenings or cooking oils
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
    • C11B5/00—Preserving by using additives, e.g. anti-oxidants
    • C11B5/0007—Organic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Botany (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
CN201380064003.5A 2012-12-06 2013-12-06 施用包含二十二碳五烯酸的组合物的方法 Pending CN104902888A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010984870.2A CN112107570A (zh) 2012-12-06 2013-12-06 施用包含二十二碳五烯酸的组合物的方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261734331P 2012-12-06 2012-12-06
US61/734,331 2012-12-06
US201361780948P 2013-03-13 2013-03-13
US61/780,948 2013-03-13
PCT/US2013/073714 WO2014089511A2 (en) 2012-12-06 2013-12-06 Methods of administering compositions comprising docosapentaenoic acid

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202010984870.2A Division CN112107570A (zh) 2012-12-06 2013-12-06 施用包含二十二碳五烯酸的组合物的方法

Publications (1)

Publication Number Publication Date
CN104902888A true CN104902888A (zh) 2015-09-09

Family

ID=50884050

Family Applications (4)

Application Number Title Priority Date Filing Date
CN201380064003.5A Pending CN104902888A (zh) 2012-12-06 2013-12-06 施用包含二十二碳五烯酸的组合物的方法
CN201380063980.3A Pending CN104937103A (zh) 2012-12-06 2013-12-06 ω-3五烯酸组合物及使用方法
CN202010984870.2A Pending CN112107570A (zh) 2012-12-06 2013-12-06 施用包含二十二碳五烯酸的组合物的方法
CN202110585483.6A Pending CN113274378A (zh) 2012-12-06 2013-12-06 ω-3五烯酸组合物及使用方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN201380063980.3A Pending CN104937103A (zh) 2012-12-06 2013-12-06 ω-3五烯酸组合物及使用方法
CN202010984870.2A Pending CN112107570A (zh) 2012-12-06 2013-12-06 施用包含二十二碳五烯酸的组合物的方法
CN202110585483.6A Pending CN113274378A (zh) 2012-12-06 2013-12-06 ω-3五烯酸组合物及使用方法

Country Status (9)

Country Link
EP (3) EP2929041A4 (https=)
JP (4) JP2016501249A (https=)
KR (3) KR20210059779A (https=)
CN (4) CN104902888A (https=)
AU (7) AU2013354979A1 (https=)
CA (2) CA2894366A1 (https=)
IN (2) IN2015MU01505A (https=)
MX (2) MX2015007082A (https=)
WO (2) WO2014089511A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101568665B1 (ko) 2015-07-21 2015-11-12 디와이오토 주식회사 모터의 맥동 전류를 증가시키는 브러시 구조
WO2018001844A1 (en) * 2016-06-28 2018-01-04 Nestec S.A. Biomarkers of blood-brain barrier dysfunction
JP2018168139A (ja) * 2016-10-21 2018-11-01 マルハニチロ株式会社 ｎ−３系不飽和脂肪酸を含む中性脂肪値の低減または上昇抑制用の組成物、並びに該組成物の製造におけるｎ−３系不飽和脂肪酸の使用
JP7099821B2 (ja) * 2017-12-20 2022-07-12 ポッカサッポロフード＆ビバレッジ株式会社 Ｐｃｓｋ９阻害剤及びコレステロール代謝改善用食品組成物
EP3586640A1 (en) 2018-06-21 2020-01-01 Nuseed Pty Ltd Dha enriched polyunsaturated fatty acid compositions
EP3586642A1 (en) 2018-06-21 2020-01-01 Nuseed Pty Ltd Ala enriched polyunsaturated fatty acid compositions
EP3586641A1 (en) 2018-06-21 2020-01-01 Nuseed Pty Ltd Dha enriched polyunsaturated fatty acid compositions
EP3586643A1 (en) 2018-06-21 2020-01-01 Nuseed Pty Ltd Dha enriched polyunsaturated fatty acid compositions

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101160065A (zh) * 2005-04-21 2008-04-09 努特里希亚公司 呼吸功能不全的治疗和预防方法
WO2012033538A1 (en) * 2010-09-10 2012-03-15 Stable Solutions Llc Method of mitigating adverse drug events using omega-3 fatty acids as a parenteral therapeutic drug vehicle
US8298554B2 (en) * 2009-04-29 2012-10-30 Amarin Pharmaceuticals Ireland Limited Stable pharmaceutical composition and methods of using same

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8819110D0 (en) * 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
GB0016045D0 (en) 2000-06-29 2000-08-23 Laxdale Limited Therapeutic combinations of fatty acids
JP2002125618A (ja) * 2000-10-30 2002-05-08 Katsuyuki Wakatsuki 健康食品
WO2007058523A1 (en) 2005-11-17 2007-05-24 N.V. Nutricia Composition with docosapentaenoic acid
NZ573719A (en) * 2006-07-05 2011-08-26 Photonz Corp Ltd Production of ultrapure eicosapentaenoic acid and polar lipids from largely heterotrophic culture of nitzschia laevis
KR100684642B1 (ko) * 2006-09-14 2007-02-22 주식회사 일신웰스 어유 유래 글리세라이드 유지 조성물 및 이의 제조방법
WO2010119319A1 (en) * 2009-03-09 2010-10-21 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture and a free fatty acid, and methods and uses thereof
US8241672B2 (en) * 2009-03-11 2012-08-14 Stable Solutions Llc Omega-3 enriched fish oil-in-water parenteral nutrition emulsions
EP3318255B1 (en) * 2009-06-15 2021-03-10 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating stroke in a subject on concomitant statin therapy
WO2012112511A1 (en) * 2011-02-16 2012-08-23 Pivotal Therapeutics, Inc. Cholesterol absorption inhibitor (azetidinone) and omega 3 fatty acids (epa, dha, dpa) for the reduction of cholesterol and for the reduction of cardiovascular events
EP2675445A1 (en) * 2011-02-16 2013-12-25 Pivotal Therapeutics, Inc. Statin and omega 3 fatty acids (epa, dha and dpa) for use in cardiovascular diseases
WO2013192109A1 (en) * 2012-06-17 2013-12-27 Matinas Biopharma, Inc. Omega-3 pentaenoic acid compositions and methods of use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101160065A (zh) * 2005-04-21 2008-04-09 努特里希亚公司 呼吸功能不全的治疗和预防方法
US8298554B2 (en) * 2009-04-29 2012-10-30 Amarin Pharmaceuticals Ireland Limited Stable pharmaceutical composition and methods of using same
WO2012033538A1 (en) * 2010-09-10 2012-03-15 Stable Solutions Llc Method of mitigating adverse drug events using omega-3 fatty acids as a parenteral therapeutic drug vehicle

Also Published As

Publication number Publication date
WO2014089511A3 (en) 2014-07-31
EP2929041A1 (en) 2015-10-14
JP6881893B2 (ja) 2021-06-02
IN2015DE05009A (https=) 2015-12-18
CN113274378A (zh) 2021-08-20
JP2016501248A (ja) 2016-01-18
JP2019172697A (ja) 2019-10-10
JP2016501249A (ja) 2016-01-18
MX2015007082A (es) 2016-01-12
JP2021120407A (ja) 2021-08-19
AU2017232203A1 (en) 2017-10-12
EP2928462A2 (en) 2015-10-14
EP3888646A1 (en) 2021-10-06
CN112107570A (zh) 2020-12-22
AU2013354979A1 (en) 2015-06-11
CN104937103A (zh) 2015-09-23
CA2894183A1 (en) 2014-06-12
EP2928462A4 (en) 2016-06-01
KR20150103671A (ko) 2015-09-11
AU2019216634A1 (en) 2019-09-05
WO2014089511A2 (en) 2014-06-12
WO2014089501A1 (en) 2014-06-12
AU2018229440A1 (en) 2018-10-04
IN2015MU01505A (https=) 2016-05-27
MX2015007085A (es) 2016-01-12
KR20210059779A (ko) 2021-05-25
AU2020203658A1 (en) 2020-06-25
AU2013354969A1 (en) 2015-06-11
KR20150103009A (ko) 2015-09-09
AU2021201865A1 (en) 2021-04-22
CA2894366A1 (en) 2014-06-12
EP2929041A4 (en) 2016-06-08

Similar Documents

Publication Publication Date Title
US20210205254A1 (en) Omega-3 pentaenoic acid compositions and methods of use
CN104902888A (zh) 施用包含二十二碳五烯酸的组合物的方法
WO2014179325A1 (en) Omega-3 fatty acid formulations for use as pharmaceutical treatment
WO2014179341A1 (en) Treatment with omega-3 fatty acid compositions
EP2968246A1 (en) Omega-3 pentaenoic acid compositions and methods of use
US20140194512A1 (en) Compositions comprising docosapentaenoic acid and methods of use

Legal Events

Date Code Title Description
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20150909